$9.20
3.66% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA

Prothena Corp. Plc Stock price

$9.20
-1.15 11.11% 1M
+2.88 45.57% 6M
-0.35 3.66% YTD
-4.47 32.70% 1Y
-51.05 84.73% 3Y
-3.10 25.20% 5Y
-53.02 85.21% 10Y
+2.00 27.78% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.35 3.66%
ISIN
IE00B91XRN20
Symbol
PRTA
Industry

Key metrics

Basic
Market capitalization
$495.2m
Enterprise Value
$164.4m
Net debt
positive
Cash
$330.8m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
42.0 | 43.9
EV/Sales
13.9 | 14.6
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
89.0%
Return on Equity
-25.1%
ROCE
-73.8%
ROIC
2,728.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$11.8m | $11.3m
EBITDA
$-221.4m | $0.0
EBIT
$-222.2m | $-215.3m
Net Income
$-280.5m | $-259.5m
Free Cash Flow
$-188.2m
Growth (TTM | estimate)
Revenue
-91.2% | -91.7%
EBITDA
-32.3% | 100.0%
EBIT
-32.1% | -39.3%
Net Income
-112.7% | -112.2%
Free Cash Flow
-21.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,878.1% | 0.0%
EBIT
-1,885.7%
Net
-2,379.6% | -2,300.2%
Free Cash Flow
-1,597.0%
More
EPS
$-5.2
FCF per Share
$-3.5
Short interest
10.4%
Employees
163
Rev per Employee
$830.0k
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Prothena Corp. Plc forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Prothena Corp. Plc forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
12 12
91% 91%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 64 64
5% 5%
539%
- Research and Development Expense 170 170
27% 27%
1,446%
-221 -221
32% 32%
-1,877%
- Depreciation and Amortization 0.90 0.90
0% 0%
8%
EBIT (Operating Income) EBIT -222 -222
32% 32%
-1,885%
Net Profit -280 -280
113% 113%
-2,379%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Neutral
Business Wire
22 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb...
Neutral
Business Wire
about one month ago
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.
Neutral
Business Wire
about 2 months ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Employees 163
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today